Peripheral transcriptomic biomarkers for early detection of sporadic Alzheimer disease?

Adva Hadar, David Gurwitz*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Alzheimer disease (AD) is the major epidemic of the 21st century, its prevalence rising along with improved human longevity. Early AD diagnosis is key to successful treatment, as currently available therapeutics only allow small benefits for diagnosed AD patients. By contrast, future therapeutics, including those already in preclinical or clinical trials, are expected to afford neu-roprotection prior to widespread brain damage and dementia. Brain imaging technologies are developing as promising tools for early AD diagnostics, yet their high cost limits their utility for screening at-risk populations. Blood or plasma transcriptomics, proteomics, and/or metabolomics may pave the way for cost-effective AD risk screening in middle-aged individuals years ahead of cognitive decline. This notion is exemplified by data mining of blood transcriptomics from a published dataset. Consortia blood sample collection and analysis from large cohorts with mild cognitive impairment followed longitudinally for their cognitive state would allow the development of a reliable and inexpensive early AD screening tool.

Original languageEnglish
Pages (from-to)293-300
Number of pages8
JournalDialogues in Clinical Neuroscience
Issue number4
StatePublished - 2018


  • Alzheimer disease
  • Bioinformatics
  • Mild cognitive impairment
  • Proteomics
  • Transcriptomics


Dive into the research topics of 'Peripheral transcriptomic biomarkers for early detection of sporadic Alzheimer disease?'. Together they form a unique fingerprint.

Cite this